## FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

| Washington, I | D.C. | 20549 |
|---------------|------|-------|
|---------------|------|-------|

| <b>STATEMENT</b> | <b>OF CHANGES</b> | IN BENEFICIAL | <b>OWNERSHIP</b> |
|------------------|-------------------|---------------|------------------|

| OMB APPROVAI           |           |  |  |  |  |  |  |  |  |  |
|------------------------|-----------|--|--|--|--|--|--|--|--|--|
| OMB Number:            | 3235-0287 |  |  |  |  |  |  |  |  |  |
| Estimated average burd | den       |  |  |  |  |  |  |  |  |  |
| hours per response:    | 0.5       |  |  |  |  |  |  |  |  |  |
|                        |           |  |  |  |  |  |  |  |  |  |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| (Last)   | LAURE   | RNA, INC.  | (Middle)          |                 | 3. C<br>11/ | 2. Issuer Name and Ticker or Trading Symbol PDL BIOPHARMA, INC. [ PDLI ]  3. Date of Earliest Transaction (Month/Day/Year) 11/30/2006                               |   |       |                     |  |                           |   | (C   | neck all app<br>X Direct<br>Office<br>below                       | icable)<br>or<br>r (give title<br>)                                      |   | 10% Owner<br>Other (specify<br>below) |  |
|--|---|------------|-------------------|-----------------|-------------|---|---|-------|---------------------|--|---------------------------|---|--|---|--|---|---------------------------------------|--|
| (Street) FREMO   |   | tate) (    | 94555<br>(Zip)    |                 |             | 4. If Amendment, Date of Original Filed (Month/Day/Year)  6. Individual or Joint/Group Filing (Cline)  X Form filed by One Reporti Form filed by More than C Person |   |       |                     |  |                           |   |  | orting Perso  | n  |   |                                       |  |
| Table I - Non-Deriva  1. Title of Security (Instr. 3)  2. Transa Date (Month/D |   |            |                   | Execution Date, |             |   | 3.<br>Transac<br>Code (I<br>8)                | ction | 4. Securi           | of, or Be<br>ities Acquir<br>d Of (D) (Ins<br>(A) o  | ed (A) or<br>str. 3, 4 an | 5. Amount of<br>Securities<br>Beneficially<br>Owned Following<br>Reported |  | 6. Ownership<br>Form: Direct<br>(D) or Indirect<br>(I) (Instr. 4) |  | 7. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |                                       |  |
|  | Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned  (e.g., puts, calls, warrants, options, convertible securities) |            |                   |                 |             |   |   |       |                     |  |                           |   |  |   |  |   |                                       |  |
|  |   |            | Transa<br>Code (I | nsaction of E   |             |   | Expiration Date (Month/Day/Year) Amo Seculuri |       |                     | 7. Title and<br>Amount of<br>Securities<br>Underlying<br>Derivative Security<br>(Instr. 3 and 4) |                           | 8. Price of<br>Derivative<br>Security<br>(Instr. 5)                       | 9. Number<br>derivative<br>Securities<br>Beneficiall<br>Owned<br>Following<br>Reported<br>Transactio<br>(Instr. 4) | ly  | 10.<br>Ownership<br>Form:<br>Direct (D)<br>or Indirect<br>(I) (Instr. 4) | Beneficial<br>Ownership<br>(Instr. 4)                             |                                       |  |
|  |   |            |                   |                 | Code        | v   | (A)   | (D)   | Date<br>Exercisable |  | xpiration<br>ate          | Title   | Amount<br>or<br>Number<br>of<br>Shares   |   |  |   |                                       |  |
| Employee<br>Stock<br>Option<br>(Right to<br>Buy)                               | \$22.69   | 11/30/2006 |                   |                 | A           |   | 5,000   |       | (1)                 | 1  | 1/30/2013                 | Common<br>Stock   | 5,000  | \$0   | 5,000  |   | D                                     |  |

## **Explanation of Responses:**

1. This option was vested with respect to 5/12 of the shares on the grant date and will vest with respect to 1/12 of the shares monthly starting on December 14, 2006.

## Remarks:

/s/ Howard Clowes by Howard 12/22/2006 Clowes, Attorney in Fact for

Laurence Jay Korn

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.